Inactive Instrument

Safal Herbs Limited

532034

INE880M01020

Safal Herbs Limited Appoints Amit Kumar Sodhani, as A Whole-Time Company Secretary Cum Compliance Officer

October 27, 2020 at 11:10 am

Safal Herbs Limited announced that the Board of Directors of Safal Herbs Limited, in their Board Meeting held on 26 October, 2020 has appointed Mr. Amit Kumar Sodhani, as a Whole-Time Company Secretary cum Compliance Officer on the Board of the Company With effect from 26 October, 2020.

Latest news about Safal Herbs Limited

Safal Herbs Limited Announces Resignation of Smita Chaturvedi Company Sceretary and Compliance Officer	10/08/22	CI
Safal Herbs Limited Approves Resignation of Mr. Rajesh Chaudhary as Director	19/07/22	CI
Safal Herbs Limited Appoints Pratha Prasad as CFO	09/09/21	CI
Safal Herbs Limited Appoints Smita Chaturvedi as Company Secretary	09/09/21	CI
Safal Herbs Limited Announces Earnings Results for the First Quarter Ended June 30, 2021	13/08/21	CI
Safal Herbs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	25/06/21	CI
Safal Herbs Limited Announces Resignation of Amit Kumar Sodhan as Company Secretary and Compliance Officer	20/03/21	CI
Safal Herbs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21	CI
Safal Herbs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	07/11/20	CI
Safal Herbs Limited Appoints Amit Kumar Sodhani, as A Whole-Time Company Secretary Cum Compliance Officer	27/10/20	CI
Safal Herbs Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	14/09/20	CI
Safal Herbs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	31/07/20	CI
Safal Herbs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	11/02/20	CI
Safal Herbs Limited Appoints Hema Lalwani as A Company Secretary	08/01/20	CI
Safal Herbs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	13/11/19	CI
Safal Herbs Limited Appoints Priya Gautam as Additional Director	06/11/19	CI
Safal Herbs Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	14/08/19	CI
Safal Herbs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	08/06/19	CI
Safal Herbs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018	16/02/19	CI
Safal Herbs Limited Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended September 30, 2018	15/11/18	CI
Safal Herbs Limited Announces Board Changes	15/05/18	CI
Safal Herbs Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	12/02/18	CI
Safal Herbs Limited Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2017	14/11/17	CI
Safal Herbs Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2017	12/08/17	CI
Safal Herbs Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2017	30/05/17	CI

Chart Safal Herbs Limited

Duration

Period

More charts

Company Profile

Safal Herbs Limited is an India-based company, which is engaged in the business of manufacturing, trading, importing, exporting, spinning, doubling, twisting, processing and dealing in all kinds of yarn. The Company focuses on various kinds of yarn, such as natural or manmade yarns, synthetic yarns, cotton yarns, natural fiber yarns and viscose rayon yarns. The Company focuses on other rayon blended yarns and viscose, cellulose, art silk, cotton wool, hemp, linen, and all other kind of fibrous materials. The Company offers other kind of fibers, polyester filament yarns, nylon type yarns and cord, and polypropylene staple fiber.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals